Bridged artificial nucleoside and nucleotide
AssigneeOsaka University
InventorsSatoshi Obika, Yoshiyuki Hari, Tetsuya Kodama, Aiko Yahara, Masaru Nishida
Life of this patent
Estimating the term…
Loading patent…
AssigneeOsaka University
InventorsSatoshi Obika, Yoshiyuki Hari, Tetsuya Kodama, Aiko Yahara, Masaru Nishida
Estimating the term…
It is an object of the present invention to provide a novel molecule for antisense therapies which is not susceptible to nuclease degradation in vivo and has a high binding affinity and specificity for the target mRNAs and which can efficiently regulate expression of specific genes. The novel artificial nucleoside of the present invention has an amide bond introduced into a bridge structure of 2′,4′-BNA/LNA. The oligonucleotide containing the 2′,4′-bridged artificial nucleotide has a binding affinity for a single-stranded RNA comparable to known 2′,4′-BNA/LNA and has an increased nuclease resistance over LNA. Particularly, it is expected to be applied to nucleic acid drugs because of its much stronger binding affinity for single-stranded RNAs than S-oligo's affinity.
A compound represented by the following formula I or formula II or a salt thereof:
An oligonucleotide containing at least one nucleoside structure represented by the following formula III or formula IV or pharmacologically acceptable salts thereof:
Dependencies are inferred from the claim text.